Date: 2012-01-27
Type of information: Services contract
Compound: small molecule lead generation services
Company: iNovacia (Sweden) Agios Pharmaceuticals (USA)
Therapeutic area:
Type agreement: R&D
services
Action mechanism:
Disease:
Details: iNovacia AB, provider of small molecule drug discovery services, has entered into a high-throughput screening collaboration with Agios Pharmaceuticals. Under the agreement, iNovacia will provide small molecule lead generation services and use its proprietary screening library to identify modulators of pharmaceutical targets of interest to Agios Pharmaceuticals. iNovacia provides high-throughput screening (HTS), fragment-based screening (FBS) and other drug discovery services to translate targets into validated leads for pharmaceutical and biotech companies.
Financial terms: Financial terms of the agreement are not disclosed.
Latest news:
